We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights: JPMorgan Chase, Gilead, ConocoPhillips, General Electric and Walgreens
Read MoreHide Full Article
For Immediate Release
Chicago, IL – October 31, 2017 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include JPMorgan Chase (JPM - Free Report) , Gilead (GILD - Free Report) , ConocoPhillips (COP - Free Report) , General Electric (GE - Free Report) and Walgreens (WBA - Free Report) .
Top Research Reports for JPMorgan, Gilead and ConocoPhillips
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including JPMorgan Chase, Gilead and ConocoPhillips. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
JPMorgan Chase shares have outperformed the Zacks Major Regional Banks industry over the past six months, (+16.9% vs. +11.7%). This price performance is backed by impressive earnings surprise history, with the company having surpassed expectations in all the trailing four quarters. The bank’s third quarter 2017 results benefited from rise in interest rates, loan growth and lower operating expenses while trading slump, weak investment banking and fall in mortgage banking income were the headwinds.
The Zacks analyst thinks that its efforts to control expenses, the improved rate scenario and rising loan demand should continue to benefit its financials. However, the company faces a persistent fee income growth challenge, mainly due to slowdown in trading activities and dismal capital markets performance. Also, legal expenses are expected to continue lingering in the near-term.
Shares of Gilead have outperformed the Zacks Biotech industry so far in 2017, increasing +7.6% vs. a gain of +3.9%. Although Gilead topped both earnings and revenue estimates in the third quarter, it witnessed a decline in HCV sales. The HCV franchise is under tremendous pressure due to lower patient starts and increasing competition. Sales are expected to decline further.
Meanwhile, the HIV franchise maintains momentum driven by the rapid adoption of TAF-based regimens in the United States and EU. The TAF-based regimens now represent 56% of total Gilead HIV prescription volume following the launch of Genvoya and the launches of Odefsey and Descovy in 2016.
The Zacks analyst thinks strong uptake for Truvada for use in the pre-exposure prophylaxis will further boost sales as the company saw a significant uptick in PrEP usage in 2017. The acquisition of Kite and approval of Yescarta also bodes well for Gilead given the potential in the CAR T therapy. However, Gilead has lost exclusivity for Viread and Truvada.
Buy-ratedConocoPhillips’ shares are up +2.1% year to date, outperforming the Zacks U.S. Integrated Oil industry, which has lost -10.4% over the same period. ConocoPhillips is one of the largest exploration and production players in the world, based on proved reserves and production.
The Zacks analyst likes the company’s initiative to divest non-core assets as the explorer could divert the proceeds toward oil-rich Eagle Ford shale and Permian Basin. Significant undrilled locations in the Eagle Ford shale will boost the company’s production.
Recently, the upstream energy firm posted strong third-quarter 2017 results, primarily supported by higher oil and natural gas price realizations. Also, utilizing an improved completion design, ConocoPhillips has managed to significantly lower well operating costs.
Other noteworthy reports we are featuring today include General Electric and Walgreens.
Zacks’ Best Private Investment Ideas
While we are happy to share many articles like this on the website, our best recommendations and most in-depth research are not available to the public.
Starting today, for the next month, you can follow all Zacks' private buys and sells in real time. Our experts cover all kinds of trades… from value to momentum . . . from stocks under $10 to ETF and option moves . . . from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises. You can even look inside exclusive portfolios that are normally closed to new investors.
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Strong Stocks that Should Be in the News
Many are little publicized and fly under the Wall Street radar. They're virtually unknown to the general public. Yet today's 220 Zacks Rank #1 "Strong Buys" were generated by the stock-picking system that has nearly tripled the market from 1988 through 2015. Its average gain has been a stellar +26% per year.See these high-potential stocks free >>.
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
The Zacks Analyst Blog Highlights: JPMorgan Chase, Gilead, ConocoPhillips, General Electric and Walgreens
For Immediate Release
Chicago, IL – October 31, 2017 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include JPMorgan Chase (JPM - Free Report) , Gilead (GILD - Free Report) , ConocoPhillips (COP - Free Report) , General Electric (GE - Free Report) and Walgreens (WBA - Free Report) .
Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.
Here are highlights from Monday’s Analyst Blog:
Top Research Reports for JPMorgan, Gilead and ConocoPhillips
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including JPMorgan Chase, Gilead and ConocoPhillips. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
JPMorgan Chase shares have outperformed the Zacks Major Regional Banks industry over the past six months, (+16.9% vs. +11.7%). This price performance is backed by impressive earnings surprise history, with the company having surpassed expectations in all the trailing four quarters. The bank’s third quarter 2017 results benefited from rise in interest rates, loan growth and lower operating expenses while trading slump, weak investment banking and fall in mortgage banking income were the headwinds.
The Zacks analyst thinks that its efforts to control expenses, the improved rate scenario and rising loan demand should continue to benefit its financials. However, the company faces a persistent fee income growth challenge, mainly due to slowdown in trading activities and dismal capital markets performance. Also, legal expenses are expected to continue lingering in the near-term.
(You can read the full research report on JPMorgan Chase here >>>).
Shares of Gilead have outperformed the Zacks Biotech industry so far in 2017, increasing +7.6% vs. a gain of +3.9%. Although Gilead topped both earnings and revenue estimates in the third quarter, it witnessed a decline in HCV sales. The HCV franchise is under tremendous pressure due to lower patient starts and increasing competition. Sales are expected to decline further.
Meanwhile, the HIV franchise maintains momentum driven by the rapid adoption of TAF-based regimens in the United States and EU. The TAF-based regimens now represent 56% of total Gilead HIV prescription volume following the launch of Genvoya and the launches of Odefsey and Descovy in 2016.
The Zacks analyst thinks strong uptake for Truvada for use in the pre-exposure prophylaxis will further boost sales as the company saw a significant uptick in PrEP usage in 2017. The acquisition of Kite and approval of Yescarta also bodes well for Gilead given the potential in the CAR T therapy. However, Gilead has lost exclusivity for Viread and Truvada.
(You can read the full research report on Gilead here >>>).
Buy-ratedConocoPhillips’ shares are up +2.1% year to date, outperforming the Zacks U.S. Integrated Oil industry, which has lost -10.4% over the same period. ConocoPhillips is one of the largest exploration and production players in the world, based on proved reserves and production.
The Zacks analyst likes the company’s initiative to divest non-core assets as the explorer could divert the proceeds toward oil-rich Eagle Ford shale and Permian Basin. Significant undrilled locations in the Eagle Ford shale will boost the company’s production.
Recently, the upstream energy firm posted strong third-quarter 2017 results, primarily supported by higher oil and natural gas price realizations. Also, utilizing an improved completion design, ConocoPhillips has managed to significantly lower well operating costs.
(You can read the full research report on ConocoPhillips here >>>).
Other noteworthy reports we are featuring today include General Electric and Walgreens.
Zacks’ Best Private Investment Ideas
While we are happy to share many articles like this on the website, our best recommendations and most in-depth research are not available to the public.
Starting today, for the next month, you can follow all Zacks' private buys and sells in real time. Our experts cover all kinds of trades… from value to momentum . . . from stocks under $10 to ETF and option moves . . . from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises. You can even look inside exclusive portfolios that are normally closed to new investors.
Click here for Zacks' private trades >>
Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1 Stock of the Day pick for free.
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Strong Stocks that Should Be in the News
Many are little publicized and fly under the Wall Street radar. They're virtually unknown to the general public. Yet today's 220 Zacks Rank #1 "Strong Buys" were generated by the stock-picking system that has nearly tripled the market from 1988 through 2015. Its average gain has been a stellar +26% per year.See these high-potential stocks free >>.
Follow us on Twitter: https://twitter.com/zacksresearch
Join us on Facebook: https://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com/
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.